Primary Endpoint
Objective:
To compare cumulative cancer-free survival up to 5 years (60 months) from randomisation between intervention (metformin) and control (no metformin) arms
Endpoint
Cancer free survival – with “cancer” event defined as pathologically confirmed diagnosis of malignant cancer identified during trial participation or death from any cause
Status
Open to Recruitment